MUSC President David Cole

  • sam patrick posted an article
    MUSC has multi-billion-dollar impact on South Carolina... see more

    A new report shows the Medical University of South Carolina has an annual economic impact on the state of about $5.6 billion. MUSC Health CEO Patrick Cawley, M.D., knows where a big part of the credit lies. “MUSC Health has grown significantly in the past 18 months and this report details the growing economic impact across the entire state of South Carolina.”

    In early 2019, MUSC bought four hospitals in Lancaster, Florence, Marion and Chester, creating a regional hospital network and establishing itself as a health care organization that reaches well beyond Charleston. 

    Joseph Von Nessen, Ph.D., a research economist at the Darla Moore School of Business at the University of South Carolina in Columbia, led the six-month economic impact study. “MUSC maintains a unique and sizeable statewide economic footprint. Its impact in Charleston may already be well known, but it’s also important to recognize that MUSC’s economic benefits extend well beyond the borders of the Tri-county region.”

    For example: “About 38,000 people in South Carolina can attribute their jobs either directly or indirectly to the activities that are going on at MUSC every day. It really shows how significant MUSC’s impact is,” Von Nessen said.

    Read the entire story here...

  • sam patrick posted an article
    Dr. David Cole chronicled many MUSC achievements during the 2020 fiscal year see more

    CHARLESTON, S.C. (Aug. 14, 2020) – Recently, the Medical University of South Carolina (MUSC) and Medical University Hospital Authority (MUHA) Board of Trustees held their regularly scheduled combined committee sessions and board meeting. With its fiscal year-end closing on June 30, MUSC administrators focused on the multilayered impacts of the novel coronavirus on the operations of all three missions of the institution – education, research and patient care – along with MUSC’s leadership role across the community and state during this pandemic. To support established social distancing guidelines in the COVID-19 era, the MUSC trustees and administrators met via teleconference.

    “The ripple effects of the pandemic continue to reach every area of our institution,” said MUSC President David J. Cole, M.D., FACS. “We are committed to battling this virus at every turn and continue to find innovative ways to deliver safe, top-quality education and patient care in the face of this challenge. In addition, we are engaged in ongoing research projects, many which, in collaboration with national networks, are designed to help define how to best treat and mitigate the impact of this virus.”

    “Throughout the pandemic, MUSC Health has been recognized and called upon as an essential health care resource, having performed nearly 138,000 diagnostic screening tests, primarily through mobile testing sites in communities across the state,” said Patrick J. Cawley, M.D., CEO of MUSC Health and vice president for Health Affairs, University. “In partnership with the state legislature, MUSC set up mobile screening and collection sites in rural and underserved areas in an intentional bid to reach those who are most vulnerable and too often underserved when it comes to health care. Reliable diagnostic and antibody testing remain key elements of managing this unprecedented statewide health challenge.”

    Despite the hurdles posed by COVID-19, Cole chronicled many MUSC achievements during the 2020 fiscal year, including:

    • The MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion opened in February.
    • MUSC became the only institution in the country to house both a Digestive Disease Research Core Center and a Center for Biomedical Research Excellence in Digestive and Liver Disease.
    • MUSC Health West Ashley Medical Pavilion opened as scheduled in December and served 10,418 patients in the first month, with 214 operative procedures.
    • The South Carolina Clinical & Translational Research Institute, one of about 60 Clinical and Translational Science Award hubs nationwide, was awarded a $24M five-year renewal.
    • Safely held a series of virtual graduation celebrations, including a drive-through diploma pick-up event for its 660 graduates.
    • Transitioned more than 3,000 students to online education in response to the novel coronavirus within 24 hours’ notice. 
    • MUSC was first in the nation to combine drive-through testing with a virtual screening platform for potential COVID-19 patients.
    • MUSC and Clemson collaborated to launch the Healthy Me – Healthy SC program to increase health access and fight health disparities statewide. The program began expanding in early 2020 after successful pilots in Anderson, Barnwell and Williamsburg counties.
    • MUSC, Clemson and Siemens Healthineers co-hosted a summit in Columbia about artificial intelligence (AI) to bring together faculty, clinicians and engineers. They shared information about current work, new opportunities and discussed the future of AI in health care. The pilot effort funded three joint AI projects with Clemson.
    • U.S. News & World Report named MUSC the state’s best hospital for the fifth consecutive year.
    • The inaugural 2019 Lowvelo Bike Ride for Cancer Research engaged more than 709 cyclists and 300 volunteers, raising some $650,000 to support MUSC Hollings Cancer Center.
    • The U.S. Patent Office granted the MUSC Foundation for Research Development 18 patents.
    • MUSC received $25 million from the General Assembly to partner with the South Carolina Department of Health and Environmental Control and the South Carolina Hospital Association to develop and deploy a statewide testing plan. The focus of the plan is on rural and underserved areas of the state. More than 200 testing events/sites have been implemented.
    • MUSC Health continues to support the reopening plan and testing strategy for the University of SC, College of Charleston, The Citadel and Clemson University.

    The 16-member MUSC/MUHA board voted unanimously to elect James Lemon, DMD, as chairman and Charles W. Schulze, CPA, as vice chairman. Each will serve a two-year term. Lemon is an oral and maxillofacial surgeon by training. A native of Barnwell, he has lived in Columbia for more than three decades. Elected to the MUSC board in 2014, he serves as the medical professional representative from the 2nd Congressional District. Schulze, a Greenwood native, began his first term as an MUSC trustee in 2002 as the lay representative from the 3rd Congressional District. A retired shareholder of a regional accounting and consulting firm, Schulze currently practices and is an expert in financial forensics.

    In other business, the board voted to approve:

    • The fiscal year 2021 budgets for MUSC (University), the MUSC Health system and MUSC Physicians. 
    • Moving the spring commencement and graduation date from its originally scheduled date of May 22 to May 15, 2021.
    • A seven-year lease to provide new clinical care space for the MUSC Neuro Rehabilitation Institute in Charleston.
    • A supplemental HVAC system for the MUSC Hollings Cancer Center Compounding Pharmacy.
    • A lease renewal to provide 140 parking spaces at the intersection of Line Street and Hagood Avenue.  

     

    The MUSC/MUHA Board of Trustees serves as separate bodies to govern the university and hospital, normally holding two days of committee and board meetings six times a year. For more information about the MUSC Board of Trustees, visit http://academicdepartments.musc.edu/leadership/board/index.html.

     

    About The Medical University of South Carolina

    Founded in 1824 in Charleston, MUSC is the oldest medical school in the South as well as the state’s only integrated academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state’s leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit musc.edu.

    As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2020, for the sixth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

    MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.

  • sam patrick posted an article
    David Zaas Named to executive post at MUSC see more

    Patrick J. Cawley, M.D., CEO for MUSC Health and vice president for Health Affairs, University, named David Zaas, M.D., MBA, as the new chief executive officer, MUSC Health - Charleston Division, and chief clinical officer for MUSC Health. In these roles, Zaas will report directly to Cawley, who leads the entire MUSC Health statewide system. Following a national search, Zaas was recommended for this major leadership position by a search committee co-chaired by Prabhakar Baliga, M.D., chair, Department of Surgery, and Lisa Montgomery, MHA, MUSC executive vice president, Finance and Operations. Zaas is scheduled to join MUSC in July. 

    As the CEO of MUSC Health - Charleston, Zaas will lead the MUSC Hospital Authority in Charleston, including the MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion. He will oversee the executive leadership team of the MUSC Health - Charleston Division and serve on the MUSC Health System Council, as CEO of our flagship hospital. His responsibility as chief clinical officer will involve providing guidance and advice on health care system strategies. 

    “Dr. Zaas has a deep appreciation for academic medicine and its critical role in research and innovation,” Cawley said. “He has a history of leading and promoting successful collaboration among a university, practice plan and health system. In addition, he is a profound advocate for patient and family centeredness and has a demonstrated track record of leading clinical growth, financial success and top performance in quality and safety. We look forward to the many contributions he can make to our health system,” he added.

    Prior to accepting his new role, Zaas served as president of Duke Raleigh Hospital since 2014. His previous leadership positions at Duke University in Durham, North Carolina, include: chief medical officer, Duke Faculty Practice Diagnostic Clinic; medical director, Duke University Hospital; vice chair, Department of Medicine, Duke University; and medical director for Lung and Heart-Lung Transplantation, Duke University Hospital. He has played a central role in advancing multiple key strategic initiatives for Duke Health, including care redesign, clinical integration and improving access for patients.

    Zaas holds a B.A. in biology from Yale University, an M.D. from Northwestern University Medical School, and an MBA from Duke University. He completed his internal medicine residency at Johns Hopkins Hospital and fellowship in pulmonary and critical care at Duke University. Zaas’s academic interests have involved both translational and clinical research focused on improving outcomes from lung transplantation including the role of infectious complications after transplant.
     

    About MUSC Health

    As the clinical health system of the Medical University of South Carolina (MUSC), MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2019, for the fifth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.

    Founded in 1824, MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care. For information on academic programs, visit musc.edu.

  • sam patrick posted an article
    BIO global CEO Jim Greenwood, Over 50 National Speakers to Present at SCBIO 2018 see more

    Conference registrations soar with sell-out expected; CEOs and top industry leaders head to Charleston for strategic partnership development, industry insights

     

    SOUTH CAROLINA – September 26, 2018BIO global CEO Jim Greenwood will join more than 50 additional national speakers at SCBIO 2018 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.

    Mr. Greenwood will address the gathering with a keynote presentation entitled “Global Perspectives for Life Sciences – Compelling Opportunity for South Carolina” the morning of the conference opening on October 24.  His presentation will be bracketed by two high-powered panel discussions – a feature panel comprised of top pharmaceutical executives entitled “Pharma’s Future in the Palmetto State and Beyond,” and followed by the Southeast US Economic Development Luncheon featuring an address by Secretary of Commerce Bobby Hitt.  The luncheon will be capped by a panel featuring life sciences economic development CEOs from across the Southeastern region.  Conference Chair and Womble Bond Dickinson partner Stephanie Yarbrough will moderate the luncheon panel.

    Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2018 at Charleston’s Gaillard Auditorium, with registration already doubling the pace of 2017.  Among committed speakers and panelists are DePuy Synthes Global Orthopedic Leader I.V. Hall, Nephron Pharmaceuticals CEO Lou Kennedy, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.

    Themed “Connect.  Collaborate.  Advance!” the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion.  Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag  and more.  Space is limited and advance registration is still available at https://www.scbio.org/events/scbio-annual-conference.

    SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. 

    SCBIO 2018 kicks off Tuesday evening October 23 with an Opening Reception for conference registrants, speakers and sponsors at The Dewberry Hotel, presented by Explore Charleston and The Dewberry.  Wednesday will feature a complete day of sessions beginning at breakfast and continuing through a gala evening reception presented by Womble Bond Dickinson.  The conference will wrap up Thursday at lunchtime. 

    “The life sciences industry is a major driver of South Carolina’s economy, and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2018.” 

    Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, DePuy Synthes, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more.  All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance and SiMT.

    As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.